recurring revenue includes revenue from product maintenance plans, other post warranty maintenance, and the implied obligation
to provide software enhancements if and when available for one year following installation. Revenue from services and software
enhancements is deferred and amortized over the service or update period, which is typically one year. Revenue related to services
performed on a time-and-materials basis is recognized when performed. Other recurring revenue represented 52% and 44% of revenue
for the years ended December 31, 2018 and 2017, respectively.
have received regulatory clearance, licensing and/or CE Mark approvals necessary for us to market the Niobe system, Cardiodrive,
and various disposable devices in the U.S., Canada, Europe, China, Japan, and various other countries.
have received regulatory clearance, licensing and/or CE Mark approvals necessary for us to market the Odyssey Solution
in the U.S., Canada, Europe, China, Japan and other selected countries and we are in the process of obtaining necessary approvals
for extending our markets in other countries.
have received regulatory clearance, licensing and/or CE Mark approvals necessary for us to market the Vdrive and Vdrive
Duo systems with the V-CAS, V-Loop and V-Sono devices in the U.S., Canada and Europe. The V-CAS Deflect
catheter advancement system has been CE Marked for sale in Europe.
Webster has received FDA approval, and CE Mark for the CARTO® RMT navigation system for use with the Niobe
system, the 4mm CELSIUS® RMT Diagnostic/Ablation Steerable Tip Catheter, the 4mm NAVISTAR® RMT Diagnostic/Ablation
Steerable Tip Catheter, the 8mm Navistar RMT DS Diagnostic/Ablation Steerable Tip Catheter, and the 3.5mm NAVISTAR®
RMT THERMOCOOL® Irrigated Tip Catheter. In addition, Biosense Webster has received FDA approval and CE Mark for
the 3.5mm CELSIUS® RMT THERMOCOOL® Irrigated Tip Catheter. Biosense Webster also received China
CFDA approval and Japan PMDA approval for the CARTO® RMT navigation system for use with the Niobe system,
and the 3.5mm NAVISTAR® RMT THERMOCOOL® Irrigated Tip Catheter. Our strategic relationship with
Biosense Webster provides for co-development of catheters that can be navigated with our system, both with and without Biosense
Webster’s 3D catheter location sensing technology. In addition, we can utilize technology which allows our system to recognize
specific disposable interventional devices in order to prevent unauthorized use of our system. See “Strategic Relationships”
below for a description of our arrangements with Biosense Webster.
INFORMATION ABOUT CUSTOMERS
from Biosense Webster Inc. related to royalties and Odyssey system sales accounted for $2.9 million and $3.3 million, or
10% and 11%, of total net revenue for the years ended December 31, 2018 and 2017, respectively. No other single customer
accounted for more than 10% of total revenue for the years ended December 31, 2018 and 2017.
have focused our clinical and commercial efforts on applications of our products primarily in electrophysiology procedures for
the treatment of arrhythmias and secondarily in complex interventional cardiology procedures for the treatment of coronary artery
disease. Our system potentially has broad applicability in other areas, such as structural heart repair, interventional neurosurgery,
interventional neuroradiology, peripheral vascular, renal denervation, pulmonology, urology, gynecology and gastrointestinal medicine,
and some of our patents may be applicable in these areas as well.
rhythmic beating of the heart results from the transmission of electrical impulses. When these electrical impulses are mistimed
or uncoordinated, the heart fails to function properly, resulting in symptoms that can range from fatigue to stroke or death.
Over 5.0 million people in the U.S. currently suffer from the resulting abnormal heart rhythms, which are known as arrhythmias.
The prevalence of arrhythmias is expected to continue to rise as the population ages and life expectancy continues to increase.
These conditions are a major physical and economic burden and are associated with stroke, heart failure, and adverse symptoms
causing patients to be very motivated to seek treatment. The combination of symptoms, prevalence and co-morbidities make arrhythmias
a major economic factor in healthcare. We believe payors are very interested in therapies that may reduce the financial impact
of these diseases.
therapies for arrhythmias often fail to adequately control the arrhythmia and may have significant side effects. Consequently,
physicians have increasingly sought more permanent, non-pharmacological, solutions for arrhythmias. The most common interventional
treatment for arrhythmias, and in particular tachyarrhythmias, where the patient’s heart rate is too high or irregular,
is an ablation procedure in which the diseased tissue giving rise to the arrhythmia is isolated or destroyed. Prior to performing
an electrophysiology ablation, a physician typically performs a diagnostic procedure in which the electrical signal patterns of
the heart wall are “mapped” to identify the heart tissue generating the aberrant electrical signals. Following the
mapping procedure, the physician may then use an ablation catheter to eliminate the aberrant signal or signal path, restoring
the heart to its normal rhythm. In cases where an ablation is anticipated, physicians will choose an ablation catheter and perform
both the mapping and ablation with the same catheter. In February 2009 the FDA approved the Biosense Webster NAVISTAR®
THERMOCOOL® irrigated catheter to be labeled for the treatment of atrial fibrillation. This is the first
device approved by the FDA to be labeled for the interventional treatment of this arrhythmia.